YIL029W-A Antibody

What is YIL029W-A in Saccharomyces cerevisiae and why is it studied?

YIL029W-A is a protein-coding gene in Saccharomyces cerevisiae (baker's yeast, strain ATCC 204508/S288c) with UniProt accession number A0A023PZE9. This gene is of interest to researchers studying fundamental eukaryotic cellular processes since yeast serves as a model organism with conserved pathways relevant to human biology. YIL029W-A has been studied in contexts of genomic organization, transcriptional regulation, and protein function in cellular metabolism. The antibody against this protein enables researchers to detect, quantify, and localize the protein product in various experimental conditions, providing insights into gene expression patterns and protein dynamics during different physiological states or genetic manipulations of yeast cells.

What validation data should I expect with YIL029W-A Antibody?

Comprehensive validation data for YIL029W-A Antibody should include:

• Specificity testing through Western blot analysis showing a band at the expected molecular weight

• Immunoprecipitation data demonstrating ability to pull down the target protein

• Cross-reactivity testing against closely related proteins

• Immunofluorescence or immunohistochemistry images showing expected subcellular localization

• Positive and negative controls including knockout/knockdown validation

• Lot-to-lot consistency data

When purchasing from established suppliers, validation certificates typically provide information on antibody production methods, characterization, and application-specific validations. Researchers should verify that the validation has been performed in conditions relevant to their experimental system.

What are the recommended applications for YIL029W-A Antibody?

The YIL029W-A Antibody (CSB-PA110694XA01SVG) is typically validated for several applications in yeast research:

• Western Blotting (WB): Optimal dilution typically ranges from 1:500 to 1:2000, depending on protein expression levels

• Immunoprecipitation (IP): Useful for protein-protein interaction studies

• Immunofluorescence (IF): For subcellular localization studies

• Chromatin Immunoprecipitation (ChIP): If the target protein binds DNA or chromatin

• Flow Cytometry: For quantitative analysis of protein expression across cell populations

Each application requires specific sample preparation protocols and optimization of antibody concentration. For novel applications, pilot experiments with positive controls are essential to establish working conditions.

How should I optimize Western blot conditions for YIL029W-A detection in yeast lysates?

Optimizing Western blot conditions for YIL029W-A detection in yeast lysates requires careful consideration of several factors:

• Sample preparation: Use either mechanical disruption (glass beads) or enzymatic methods (zymolyase) for yeast cell wall disruption. Include protease inhibitors to prevent protein degradation.

• Protein extraction buffer: For membrane-associated proteins, include appropriate detergents (0.1-1% Triton X-100 or NP-40). Adjust buffer conditions based on protein characteristics.

• Gel percentage selection: Choose 10-15% polyacrylamide gels for optimal separation based on the predicted molecular weight of YIL029W-A.

• Transfer conditions: For yeast proteins, semi-dry transfer at 15-25V for 30-45 minutes or wet transfer at 30V overnight at 4°C often yields better results than standard protocols.

• Blocking optimization: Test both 5% BSA and 5% non-fat milk to determine which provides lower background with this specific antibody.

• Antibody dilution: Begin with manufacturer's recommended dilution (typically 1:1000) and adjust based on signal strength and background.

• Detection system: Enhanced chemiluminescence (ECL) systems offer good sensitivity, while fluorescent secondary antibodies provide better quantitative analysis.

Always include positive controls (wild-type yeast extract) and negative controls (YIL029W-A deletion strain if available) to validate specificity.

What approaches can I use to verify YIL029W-A Antibody specificity in my experimental system?

Verifying antibody specificity is critical for reliable research outcomes. For YIL029W-A Antibody, employ these complementary approaches:

• Genetic approaches:

  • Compare signal between wild-type and YIL029W-A knockout/knockdown strains

  • Use strains with tagged versions of YIL029W-A (HA, FLAG, etc.) and perform parallel detection with tag-specific antibodies

• Biochemical approaches:

  • Peptide competition assay: Pre-incubate antibody with excess immunizing peptide to block specific binding

  • Immunodepletion: Remove antibody reactivity through sequential incubation with target protein

  • Two-dimensional gel electrophoresis followed by Western blotting to confirm specificity based on both molecular weight and isoelectric point

• Mass spectrometry validation:

  • Immunoprecipitate the protein using the antibody

  • Analyze the precipitated protein by mass spectrometry to confirm identity

• Cross-reactivity assessment:

  • Test against closely related yeast proteins predicted by sequence homology

  • Evaluate performance in other yeast species if cross-reactivity is claimed

Documentation of these validation experiments strengthens the reliability of subsequent research findings and should be included in methods sections of publications.

What factors affect YIL029W-A protein detection in different yeast growth phases?

YIL029W-A protein detection can vary significantly across yeast growth phases due to several factors:

• Transcriptional regulation: YIL029W-A gene expression may be growth phase-dependent, with expression profiles varying between log phase, diauxic shift, and stationary phase.

• Post-translational modifications: Phosphorylation, ubiquitination, or other modifications may alter antibody recognition or protein stability in different growth phases.

• Protein localization changes: Subcellular redistribution of the protein can affect extraction efficiency using different lysis methods.

• Protein stability: Turnover rates may differ across growth phases due to proteolytic activity changes or stress responses.

• Metabolic state influence: Carbon source utilization (fermentative vs. respiratory growth) can significantly impact yeast protein expression patterns.

To account for these variations:

• Standardize harvest points using growth curves and OD600 measurements

• Consider time-course experiments to capture dynamic changes

• Adjust lysis conditions for different growth phases (stationary phase cells typically have thicker cell walls)

• Include loading controls appropriate for the growth phase being studied

• Document media composition and growth conditions thoroughly

Normalization to total protein or housekeeping genes should be performed with caution, as traditional housekeeping genes may also exhibit growth phase-dependent expression.

How can I resolve weak or absent signal issues when using YIL029W-A Antibody?

When encountering weak or absent signals with YIL029W-A Antibody, systematically troubleshoot using this approach:

• Sample preparation issues:

  • Verify protein extraction efficiency using Bradford/BCA assays

  • Ensure protease inhibitors are fresh and complete

  • For difficult extractions, try alternative lysis methods (mechanical vs. enzymatic)

  • Check protein degradation by Coomassie staining of parallel gels

• Antibody-related considerations:

  • Confirm antibody storage conditions (avoid repeated freeze-thaw cycles)

  • Test increased antibody concentration (up to 5x manufacturer recommendation)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Try alternative detection systems with higher sensitivity

• Technical optimizations:

  • Increase protein loading (up to 50-100 μg per lane)

  • Reduce washing stringency temporarily to assess if signal is being lost

  • Try alternative membrane types (PVDF vs. nitrocellulose)

  • Enhance transfer efficiency with lower percentage gels or longer transfer times

• Biological considerations:

  • Verify if the protein is expressed under your specific experimental conditions

  • Consider if post-translational modifications might affect epitope recognition

  • Test different yeast growth phases as expression may be condition-dependent

Document all optimization steps systematically to establish reliable detection protocols for future experiments.

What cross-reactivity concerns exist when using YIL029W-A Antibody in related yeast species?

Cross-reactivity considerations when using YIL029W-A Antibody across different yeast species include:

• Sequence homology assessment:

  • Perform bioinformatic analysis of the immunizing epitope sequence across target species

  • Identify homologs with >70% sequence identity that might cross-react

  • Pay particular attention to conserved domains within the protein family

• Experimental validation strategies:

  • Test antibody performance in closely related Saccharomyces species (S. paradoxus, S. bayanus)

  • Validate in more distant yeasts (Candida, Schizosaccharomyces) if broader applications are intended

  • Use species-specific knockout controls whenever possible

• Cross-reactivity documentation:

  • Create a validation matrix of tested species and applications

  • Document band patterns and molecular weights in different species

  • Note species-specific sample preparation modifications required

• Potential confounding factors:

  • Differences in post-translational modifications between species

  • Variation in protein expression levels requiring adjusted antibody concentrations

  • Species-specific binding proteins that might generate false positive signals

When publishing data from cross-species applications, include explicit validation data demonstrating specificity in each organism studied. Consider epitope mapping if cross-reactivity patterns are complex.

How can I optimize immunoprecipitation protocols for protein interaction studies with YIL029W-A?

Optimizing immunoprecipitation (IP) for YIL029W-A protein interaction studies requires careful attention to multiple factors:

• Lysis buffer composition:

  • Start with standard IP buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40)

  • Adjust salt concentration (100-500 mM) to modulate stringency

  • Test different detergents (NP-40, Triton X-100, CHAPS) at various concentrations (0.1-1%)

  • Include protease and phosphatase inhibitors to preserve interactions

• Antibody coupling strategies:

  • Direct approach: Incubate lysate with YIL029W-A antibody, then capture with Protein A/G beads

  • Pre-coupling approach: Attach antibody to beads first, then incubate with lysate

  • Consider covalent coupling to beads for cleaner results and to avoid antibody contamination

• Incubation conditions:

  • Compare short (1-2 hours) vs. long (overnight) incubations at 4°C

  • Test different lysate:antibody ratios to optimize signal-to-noise

  • Include gentle rotation to maintain bead suspension without disrupting complexes

• Washing optimization:

  • Develop a washing stringency gradient to determine optimal conditions

  • Compare different wash buffer compositions and numbers of washes

  • Consider detergent reduction in later washes to preserve weaker interactions

• Elution strategies:

  • Compare specific elution with immunizing peptide vs. harsh elution (SDS, low pH)

  • For mass spectrometry applications, optimize elution compatibility with downstream analysis

• Controls:

  • Include IgG control IP from same species as YIL029W-A antibody

  • Perform IP from YIL029W-A knockout strain as negative control

  • Consider reciprocal IPs of identified interaction partners to confirm relationships

Document all optimization steps methodically, as small technical variations can significantly impact the interactome detected.

How should I quantify and normalize YIL029W-A protein expression in comparative studies?

Proper quantification and normalization of YIL029W-A protein expression in comparative studies requires rigorous methodology:

• Quantification approaches:

  • Densitometry analysis of Western blots using linear range exposures

  • Fluorescent secondary antibodies for wider dynamic range quantification

  • Consider analytical software (ImageJ, Li-COR Image Studio) with background subtraction

• Normalization strategies:

  • Total protein normalization using stain-free technology or Ponceau S staining

  • Housekeeping protein normalization with caution (verify stability across conditions)

  • Multiple reference gene approach for improved reliability

  • Consider normalization to cell number or OD600 for whole-culture studies

• Technical considerations:

  • Include standard curves with recombinant protein if absolute quantification is needed

  • Run biological replicates (n≥3) on separate gels with identical conditions

  • Include inter-gel calibrators if comparing across multiple blots

  • Document image acquisition settings and maintain consistency

• Statistical analysis:

  • Apply appropriate statistical tests based on experimental design

  • Report variability (standard deviation, standard error, confidence intervals)

  • Consider power analysis to determine required sample size

  • Use non-parametric tests if normality cannot be established

• Data presentation:

  • Show representative images alongside quantification

  • Include all data points in graphs, not just means

  • Clearly indicate sample sizes and statistical significance

  • Provide raw densitometry data in supplements or repositories

This comprehensive approach ensures robust quantitative comparisons that meet current standards for reproducible research.

What are the implications of post-translational modifications on YIL029W-A Antibody recognition?

Post-translational modifications (PTMs) can significantly impact YIL029W-A Antibody recognition, with important research implications:

• Common PTMs affecting antibody recognition:

  • Phosphorylation: Can create or mask epitopes depending on modification site

  • Ubiquitination: May sterically hinder antibody access to epitopes

  • Glycosylation: Can completely block antibody binding to modified regions

  • Proteolytic processing: May remove epitope regions entirely

• Experimental approaches to assess PTM impact:

  • Phosphatase treatment of samples to remove phosphorylation

  • Use of deglycosylation enzymes to remove glycan modifications

  • Comparison of reducing vs. non-reducing conditions for disulfide-dependent epitopes

  • Proteomic analysis to map modification sites relative to antibody epitope

• Antibody selection considerations:

  • Determine if the antibody was raised against a modified or unmodified peptide

  • Request information about the immunizing epitope sequence

  • Consider using multiple antibodies targeting different regions of YIL029W-A

  • Test PTM-specific antibodies if modifications are of research interest

• Experimental design implications:

  • Document growth conditions that may affect modification states

  • Consider how experimental manipulations might alter PTM profiles

  • Include appropriate controls when studying PTM-dependent functions

  • Interpret negative results cautiously when modifications might explain absence of signal

Understanding the relationship between PTMs and antibody recognition is crucial for accurate interpretation of experimental results, especially when studying YIL029W-A under different physiological or stress conditions.

How can YIL029W-A Antibody be used in chromatin immunoprecipitation (ChIP) experiments?

Using YIL029W-A Antibody in chromatin immunoprecipitation (ChIP) experiments requires specific considerations for optimal results:

• Experimental prerequisites:

  • Verify if YIL029W-A has DNA-binding properties or chromatin association

  • Confirm antibody specificity in ChIP-compatible fixation conditions

  • Determine if the epitope remains accessible after formaldehyde crosslinking

• ChIP protocol adaptations for yeast:

  • Cell wall disruption optimization: Enzymatic (zymolyase) vs. mechanical disruption

  • Crosslinking conditions: Standard formaldehyde (1%) for 10-15 minutes at room temperature

  • Sonication parameters: Typically 10-15 cycles (30s on/30s off) to achieve 200-500bp fragments

  • Chromatin quantity: Start with 1×10^8 cells per IP reaction

• Controls and validation:

  • Input DNA (pre-immunoprecipitation) as normalization control

  • IgG control from same species as YIL029W-A antibody

  • Positive control: ChIP against known DNA-binding protein

  • Negative control: Non-transcribed region for background assessment

• Data analysis considerations:

  • qPCR analysis of candidate binding regions

  • ChIP-seq for genome-wide binding profile

  • Peak calling algorithms appropriate for transcription factors vs. histone modifications

  • Data normalization to input and IgG controls

• Troubleshooting strategies:

  • Epitope masking: Try different antibodies targeting different regions

  • Crosslinking optimization: Test different crosslinking times or dual crosslinking

  • Stringency adjustment: Modify wash buffers to reduce background

  • Sonication efficiency: Verify fragment size distribution by gel electrophoresis

When publishing ChIP data, include detailed methods and quality control metrics to ensure reproducibility across laboratories.

How does the performance of YIL029W-A Antibody compare in different detection systems?

Comparative analysis of YIL029W-A Antibody performance across detection systems reveals important considerations for experimental design:

• Chemiluminescence detection systems:

  • Standard ECL: Adequate for medium-to-high abundance proteins, cost-effective

  • Enhanced ECL (ECL Plus, Femto): Higher sensitivity for low abundance targets, but increased background

  • Exposure optimization: Signal linearity typically maintained for 10-100 fold range

• Fluorescent detection systems:

  • Advantages: Wider linear dynamic range (up to 4-5 logs), multiplexing capability

  • Considerations: Requires specialized scanners, higher initial antibody quantities

  • Performance: Often superior for quantitative analysis and normalization

• Colorimetric detection systems:

  • Advantages: Stability, no specialized equipment, direct visualization

  • Limitations: Lower sensitivity, narrower linear range, less suitable for quantification

  • Applications: Best for highly abundant proteins or qualitative analysis

• Detection system-specific optimizations:

  • Antibody dilution: Typically 1:500-1:1000 for chemiluminescence; 1:200-1:500 for fluorescent

  • Incubation times: May require longer incubations for colorimetric detection

  • Membrane selection: PVDF often preferred for fluorescence; nitrocellulose for chemiluminescence

• Quantitative comparison metrics:

  • Signal-to-noise ratio across systems under standardized conditions

  • Linear dynamic range assessment with dilution series

  • Lot-to-lot consistency evaluation in different detection platforms

Researchers should select detection systems based on specific experimental requirements for sensitivity, quantification needs, and available instrumentation.

What approaches should I use to study YIL029W-A protein-protein interactions in yeast?

Studying YIL029W-A protein-protein interactions in yeast requires multiple complementary approaches:

• Affinity purification coupled with mass spectrometry (AP-MS):

  • Tag YIL029W-A with epitope tags (TAP, FLAG, HA) through genomic integration

  • Perform single-step or tandem affinity purification

  • Analyze by mass spectrometry to identify interaction partners

  • Use SAINT or other statistical models to distinguish true interactions from contaminants

• Yeast two-hybrid (Y2H) analysis:

  • Clone YIL029W-A as bait in appropriate Y2H vectors

  • Screen against yeast genomic or cDNA libraries

  • Perform directed Y2H to test specific predicted interactions

  • Validate with deletion constructs to map interaction domains

• Bimolecular fluorescence complementation (BiFC):

  • Fuse YIL029W-A and candidate partners to complementary fragments of fluorescent proteins

  • Reconstitution of fluorescence indicates proximity in living cells

  • Provides spatial information about interaction sites within cells

• Proximity-dependent biotin identification (BioID):

  • Fuse YIL029W-A to a promiscuous biotin ligase

  • Identify proximity partners through streptavidin purification and mass spectrometry

  • Captures transient interactions difficult to detect by other methods

• Co-immunoprecipitation with YIL029W-A Antibody:

  • Perform native IP from yeast lysates

  • Identify partners through Western blotting or mass spectrometry

  • Verify interactions with reciprocal co-IPs

• Integration of multiple datasets:

  • Cross-validate interactions identified by different methods

  • Use computational approaches to assess confidence in interaction networks

  • Consider functional relationship evidence (genetic interactions, co-expression)

Combining these approaches provides robust evidence for protein interactions and helps distinguish direct from indirect interactions within complexes.

How can I design experiments to study the functional significance of YIL029W-A in yeast cellular processes?

Designing experiments to study YIL029W-A function requires a systematic approach combining genetic, biochemical, and cell biological methods:

• Genetic manipulation strategies:

  • Generate complete gene deletion strain (confirm phenotypes across different genetic backgrounds)

  • Create conditional alleles (temperature-sensitive, auxin-inducible degron)

  • Employ precise mutagenesis of key residues based on sequence analysis

  • Construct domain deletion variants to map functional regions

• Phenotypic characterization:

  • Growth assays under various conditions (temperature, carbon sources, stress)

  • Cell cycle analysis by flow cytometry and microscopy

  • Metabolic profiling to identify biochemical pathways affected

  • Systematic genetic interaction screens (synthetic lethality, suppressor screens)

• Localization and dynamics studies:

  • GFP-tagging at endogenous locus to monitor localization

  • Time-lapse microscopy to track dynamics during cell cycle or stress response

  • Co-localization with organelle markers to determine subcellular compartmentalization

  • FRAP analysis to assess protein mobility and turnover

• Molecular function assessment:

  • RNA-seq to identify transcriptional changes in deletion/mutation strains

  • Proteomics to identify altered protein levels or post-translational modifications

  • Metabolomics to detect changes in metabolic pathways

  • Chromatin association studies if nuclear function is suspected

• Evolutionary conservation analysis:

  • Complementation studies with homologs from related species

  • Cross-species functional assays to determine conserved functions

  • Bioinformatic analysis of selection pressures on protein sequence

• Integration with existing knowledge:

  • Connect findings with known cellular pathways and processes

  • Place YIL029W-A in the context of protein interaction networks

  • Compare phenotypes with functionally related genes

This comprehensive approach allows for detailed functional characterization while providing multiple lines of evidence for the biological role of YIL029W-A in yeast cellular processes.